Breaking News Instant updates and real-time market news.

UNP

Union Pacific

$169.20

0.7 (0.42%)

08:13
04/18/19
04/18
08:13
04/18/19
08:13

Union Pacific CEO says dealt with 'significant weather challenges' in Q1

"We delivered record first quarter financial results driven by improved operating performance, while dealing with significant weather challenges," said Lance Fritz, Union Pacific chairman, president and CEO. "Unified Plan 2020 created a more resilient and robust network, allowing us to quickly return to normal operations."

  • 18

    Apr

  • 16

    May

UNP Union Pacific
$169.20

0.7 (0.42%)

01/24/19
LOOP
01/24/19
NO CHANGE
Target $193
LOOP
Buy
Loop raises Union Pacific price target to $193, sees good fortune continuing
Following Union Pacific's Q4 earnings report, Loop Capital analyst Rick Paterson said it is "a little remarkable how Union Pacific's fortunes have inflected to the positive since October," though he sees "more to come" for the stock. Union Pacific had seemed determined to implement PSR primarily with in-house talent prior to hiring Jim Vena, and operating metrics following the October phase I implementation evidenced a strong start, but the Vena hire "was clearly a positive" and "the icing on the cake in terms of investor sentiment," Paterson added. He raised his price target on Union Pacific shares to $193 from $188 and keeps a Buy rating on the stock.
01/25/19
ARGS
01/25/19
NO CHANGE
Target $175
ARGS
Buy
Union Pacific price target raised to $175 from $155 at Argus
Argus analyst John Eade raised his price target on Union Pacific to $175 and kept his Buy rating, saying the stock is in "recovery mode" given the recent improvement in the energy market. The analyst also points to the "strengthening underlying demand for rail transport" and more positive overall volume trends, adding that the company's earnings are further supported by its industry-low operating ratio.
03/19/19
LOOP
03/19/19
DOWNGRADE
Target $182
LOOP
Hold
Union Pacific downgraded to Hold from Buy at Loop Capital
Loop Capital analyst Rick Paterson downgraded Union Pacific to Hold from Buy and lowered his price target for the shares to $182 from $193.
03/19/19
03/19/19
DOWNGRADE
Target $182

Hold
Union Pacific cut to Hold at Loop Capital on cold weather, Nebraska flooding
As previously reported, Loop Capital analyst Rick Paterson downgraded Union Pacific to Hold from Buy and lowered his price target to $182 from $193. Amid the meltdown of western railroads, the analyst says Union Pacific "wins the award for the world's unluckiest", noting that in spite of reeling from the Oregon tunnel collapse last May, the more recent polar vortex and Nebraska flooding delivered a "one-two punch" to the company. Paterson also lowers his FY19 EPS view to $8.72 from $8.86 and FY20 forecast to $9.95 from $10.09 on Union Pacific and sees its P/E topping at 18-times, stating it "makes sense to scale back" the rating.

TODAY'S FREE FLY STORIES

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

06:55
12/08/19
12/08
06:55
12/08/19
06:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

RUHN

Ruhnn

$6.19

-0.2 (-3.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Ruhnn management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:31
12/07/19
12/07
19:31
12/07/19
19:31
Hot Stocks
Magenta reports results from MGTA-145 stem cell mobilization program »

Magenta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

PFE

Pfizer

$38.29

0.26 (0.68%)

, BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:29
12/07/19
12/07
19:29
12/07/19
19:29
Hot Stocks
Bristol-Myers Squibb-Pfizer Alliance reports analysis of Eliquis »

The Bristol-Myers…

PFE

Pfizer

$38.29

0.26 (0.68%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

UMRX

Unum Therapeutics

$0.70

0.0177 (2.61%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Hot Stocks
Unum Therapeutics announces Phase 1 clinical updates for T-cell therapies »

Unum Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Conference/Events
Magenta Therapeutics to hold an investor and analyst event »

Investor and Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

19:23
12/07/19
12/07
19:23
12/07/19
19:23
Hot Stocks
Autolus presents new data on T cell therapies in leukemia, lymphoma »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 09

    Dec

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:19
12/07/19
12/07
19:19
12/07/19
19:19
Hot Stocks
Bristol-Myers says lisocabtagene maraleucel study met both endpoints »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

SGEN

Seattle Genetics

$117.52

0.37 (0.32%)

19:16
12/07/19
12/07
19:16
12/07/19
19:16
Hot Stocks
Seattle Genetics reports updated Adcetris plus Opdivo Hodgkin lymphoma data »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 15

    Mar

GILD

Gilead

$67.09

1.16 (1.76%)

19:12
12/07/19
12/07
19:12
12/07/19
19:12
Hot Stocks
Gilead's Kite announces long-term data from ZUMA-1 study in lymphoma »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CRTX

Cortexyme

$28.00

-6.15 (-18.01%)

19:10
12/07/19
12/07
19:10
12/07/19
19:10
Hot Stocks
Cortexyme says COR388 reduced levels of ApoE protein in Phase I study »

Cortexyme announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$3.40

0.015 (0.44%)

12:15
12/07/19
12/07
12:15
12/07/19
12:15
Hot Stocks
Mallinckrodt presents data on infantile spasms predictive model »

Mallinckrodt announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

12:13
12/07/19
12/07
12:13
12/07/19
12:13
Hot Stocks
Stoke Therapeutics presents preclinical data from studies of STK-001 »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTO

Aptose Biosciences

$2.55

-0.04 (-1.54%)

12:11
12/07/19
12/07
12:11
12/07/19
12:11
Hot Stocks
Aptose reports CG-806 data in patients with chronic lymphocytic leukemia »

Aptose Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$18.22

2.9 (18.93%)

10:09
12/07/19
12/07
10:09
12/07/19
10:09
Hot Stocks
Epizyme announces 'positive, mature data' for Phase 2 trial of tazemetostat »

Epizyme reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 18

    Dec

  • 23

    Jan

PRNB

Principia Biopharma

$37.30

0.86 (2.36%)

10:07
12/07/19
12/07
10:07
12/07/19
10:07
Hot Stocks
Principia Biopharma announces 'consistent positive data' for PRN1008 »

Principia Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$200.99

1.64 (0.82%)

, GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

09:31
12/07/19
12/07
09:31
12/07/19
09:31
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$200.99

1.64 (0.82%)

GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

GOOG

Alphabet

$1,341.23

12.23 (0.92%)

AAPL

Apple

$270.71

5.15 (1.94%)

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

SQ

Square

$68.00

0.85 (1.27%)

TWTR

Twitter

$30.19

0.16 (0.53%)

CSIQ

Canadian Solar

$18.35

0.39 (2.17%)

FSLR

First Solar

$53.36

1.06 (2.03%)

JASO

JA Solar

$0.00

(0.00%)

SPWR

SunPower

$7.23

0.15 (2.12%)

TSL

Trina Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

AKS

AK Steel

$3.24

0.065 (2.05%)

MT

ArcelorMittal

$17.88

0.43 (2.46%)

NUE

Nucor

$57.60

1.13 (2.00%)

STLD

Steel Dynamics

$35.10

0.67 (1.95%)

TMST

TimkenSteel

$6.90

0.41 (6.32%)

X

U.S. Steel

$13.95

0.615 (4.61%)

AA

Alcoa

$20.60

0.68 (3.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 06

    Feb

  • 26

    Feb

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

09:27
12/07/19
12/07
09:27
12/07/19
09:27
Hot Stocks
Fate Therapeutics reports initial clinical data for FT516 and FT50 »

Fate Therapeutics …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

09:25
12/07/19
12/07
09:25
12/07/19
09:25
Conference/Events
JPMorgan enterprise software analyst to hold an analyst/industry conference call »

Software Analyst Murphy,…

CRVS

Corvus Pharmaceuticals

$4.26

-0.36 (-7.79%)

09:23
12/07/19
12/07
09:23
12/07/19
09:23
Hot Stocks
Corvus reports initial results from Phase 1/1b trial of CPI-818 »

Corvus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:21
12/07/19
12/07
09:21
12/07/19
09:21
Hot Stocks
Karyopharm announces updated Xpovio data in multiple myeloma »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

09:18
12/07/19
12/07
09:18
12/07/19
09:18
Hot Stocks
AbbVie reports results of 7.5-year pooled analysis of Imbruvica »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

09:16
12/07/19
12/07
09:16
12/07/19
09:16
Hot Stocks
Sierra Oncology reports new analyses of momelotinib compared to ruxolitinib »

Sierra Oncology reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.